XETRM3V
Market cap46mUSD
Dec 23, Last price
24.60EUR
1D
0.82%
1Q
6.96%
Jan 2017
-35.18%
IPO
-50.80%
Name
Mevis Medical Solutions AG
Chart & Performance
P/E
9.10
P/S
2.58
EPS
2.70
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
10.57%
Revenues
17m
-7.57%
Net income
5m
-36.84%
CFO
6m
+20.52%
Dividend
Mar 20, 20240.95 EUR/sh
Earnings
Jan 27, 2025
Profile
MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological disorders. It offers X-ray modalities, including computed tomography, digital mammography, digital tomosynthesis, magnetic resonance imaging, and digital sonography; and provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. The company also offers three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians, as well as internet-based special applications in teleradiology. In addition, its services are used for technical visualization and online training. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Deutschland AG.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 17,342 -7.57% | 18,762 15.71% | ||||||||
Cost of revenue | 10,781 | 1,191 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 6,561 | 17,571 | ||||||||
NOPBT Margin | 37.83% | 93.65% | ||||||||
Operating Taxes | 114 | 87 | ||||||||
Tax Rate | 1.74% | 0.50% | ||||||||
NOPAT | 6,447 | 17,484 | ||||||||
Net income | 4,920 -36.84% | 7,789 71.35% | ||||||||
Dividends | (4,546) | |||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | (1,517) | |||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 3,379 | 3,534 | ||||||||
Net debt | (8,056) | (27,375) | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | 5,854 | 4,857 | ||||||||
CAPEX | (80) | |||||||||
Cash from investing activities | 990 | 59 | ||||||||
Cash from financing activities | (7,789) | |||||||||
FCF | 6,463 | 17,444 | ||||||||
| Balance | ||||||||||
Cash | 7,744 | 9,320 | ||||||||
Long term investments | 312 | 16,537 | ||||||||
Excess cash | 7,189 | 24,920 | ||||||||
Stockholders' equity | 6,365 | 6,365 | ||||||||
Invested Capital | 14,841 | 13,350 | ||||||||
ROIC | 45.74% | 135.85% | ||||||||
ROCE | 30.94% | 88.37% | ||||||||
| EV | ||||||||||
Common stock shares outstanding | 1,820 | 1,820 | ||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 6,657 | 17,664 | ||||||||
EV/EBITDA | ||||||||||
Interest | 43 | 4 | ||||||||
Interest/NOPBT | 0.65% | 0.02% | ||||||||